Please login to the form below

Not currently logged in
Email:
Password:

EPEMED appoints executive director

Dr Anne Bruinvels takes leading role at European personalised medicine association, EPEMED

European personalised medicine association, EPEMED, has announced Dr Anne Bruinvels as its new executive director. She is an entrepreneur in personalised healthcare and will be responsible for growing the start-up organisation and building its strategic framework.

The not-for-profit group was established in late 2009 to bring together global forces in personalised medicine. Dr Bruinvels will work with the board to create guidance for all those involved in progressing personalised medicine and European market challenges in particular.

"I'm very pleased with the appointment of Dr Anne Bruinvels as executive director and board member of EPEMED," said Dr Alain Huriez, founder and president of EPEMED.

"Her proven leadership and communication skills in the personalised medicine field will benefit the association greatly and I look forward to working with her to bring harmonisation and education to the personalised medicine field in Europe."

Dr Bruinvels has worked in this arena for over 10 years. She founded personalised healthcare advisory firm, Elixior, and prior to that Curidium, a personalised medicine company identifying companion diagnostics and therapeutics to treat patients with central nervous system disorders. She has also been a researcher for SmithKline Beecham, Wyeth and Sandoz.

She obtained her PhD (neuroscience) from Utrecht University (the Netherlands) and her MSc (pharmacy) from Groningen University (the Netherlands).

3rd June 2010

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Six Degrees Medical Consulting

For over a decade, our medical communication services have helped pharmaceutical companies optimize their brand, disease and corporate objectives. Building...

Latest intelligence

white house
Eliminating pharmaceutical rebates, is this déjà vu?
By Andrew Parece and Matthew Majewski...
Patients are ready to embrace decentralised clinical trials, are you?
Traditional clinical trial designs simply can’t withstand the impact of COVID-19. While before the pandemic, some in clinical research were beginning to adopt virtual components, the move towards designing hybrid...
Has the pandemic opened up a future of accelerated diagnosis and better care for rare disease patients?
The challenge with rare disease is in the name – it's rare, so awareness is limited and diagnosis hindered. Could a more virtual existence change this? A Medical Affairs viewpoint...

Infographics